GeoVax Labs, Inc. (GOVX)
Chart Events
Performance Outlook
| Previous Close | 0.6709 |
| Open | 0.6706 |
| Bid | 0.7350 x 1000 |
| Ask | 0.7600 x 1000 |
| Day's Range | 0.6706 - 0.8300 |
| 52 Week Range | 0.5500 - 7.5000 |
| Volume | |
| Avg. Volume | 1,004,350 |
| Market Cap | 4.726M |
| Beta (5Y Monthly) | 1.89 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.1290 |
| Earnings Date | Mar 21, 2022 - Mar 25, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.00 |
- GlobeNewswire
GeoVax Announces Upcoming Presentations at Scientific Conferences
ATLANTA, GA, May 04, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire –GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, announced today that it will be represented during presentations at the following upcoming scientific conferences. 2022 National Biotechnology Conference, Anaheim, CA, May 9-12 On May 11, Mary Hauser, PhD, GeoVax Director, Preclinical Research, will deliver a presentation titled, Strategic P
- GlobeNewswire
GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update
Company Advancing Phase 2 Clinical Trials for COVID-19 and Immuno-Oncology ATLANTA, GA, April 27, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NasdaqCM: GOVX), a biotechnology company developing vaccines and immunotherapies against infectious diseases and cancers, today announced its financial results for the three months ended March 31, 2022. GeoVax’s management will host a live conference call and webcast at 4:30 p.m. Eastern Standard Time on Wednesday, April 27 to discuss f
- Benzinga
GeoVax Labs Stock Jumps On US Patent For Malaria Vaccine Candidate
The U.S. Patent and Trademark Office has issued Patent No. 11,311,612 covering GeoVax Labs Inc's (NASDAQ: GOVX) modified vaccinia Ankara (MVA) vector expressing certain antigens from the malaria parasite. GeoVax's MVA-VLP malaria vaccine candidates incorporate antigens derived from multiple stages of the parasite's life cycle. They are designed to induce an immune response with durable functional antibodies and CD4+ and CD8+ T cell responses. GeoVax's GV-MVA-VLP vaccine platform utilizes modifie
